Ascendia

  MARKET NEWS

NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben
ESTEVE CDMO Commences $15.5 Million Expansion of Chicago Small Molecule API Facility
Bioxytran Reports Positive Study Results for a Broad-Range Antiviral Drug in Mild-to-Moderate COVID-19
Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
MGS Acquires European-Based Medical Injection Molder Knudsen Plast A/S
TARA-002 Demonstrates 68% Complete Response Rate at 6 Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
etherna´s Intratumoral mRNA/LNP Platform Advances to Clinical Testing in Nonmelanoma Skin Cancer Led by Almirall
SolasCure Completes Phase 2 Clinical Trial Demonstrating Accelerated Healing With Aurase Wound Gel
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

  EXPERT CONTENT & RESOURCES

Serán Bioscience presentation title slide: 'Right from the Start: Drug Product Design for Rapid Clinical Development' by Micah Tuttle

VIDEO - Built for the Clinic: Smart Drug Product Design for Accelerated Clinical Development

In this talk, Micah Tuttle demonstrates how intentional, forward-looking drug product design from day one can dramatically accelerate clinical development—eliminating the need for costly, time-consuming reformulations and bridging studies.

Dr. Steven Quay, Founder and CEO of Atossa Therapeutics

Atossa Therapeutics: Unlocking the Platform Potential of (Z)-Endoxifen Across Oncology & Rare Disease

Dr. Steven Quay explains how (Z)-endoxifen is being positioned as both an oncology backbone therapy and a potential treatment in rare diseases with substantial unmet need.

Jinying Ning, PhD

Drug Combination Screening in Oncology: Advancing Predictive Strategies for Precision Drug Development

Jinying Ning, PhD, reports combination therapy is no longer an optional strategy in oncology drug development. The biological complexity of cancer demands approaches that account for pathway redundancy, adaptive resistance, and tumor heterogeneity.

Single B Cell Antibody Discovery: Improving Therapeutic Candidate Selection in Drug Development

Single B Cell Antibody Discovery: Improving Therapeutic Candidate Selection in Drug Development

Changchun Zha says as therapeutic pipelines become more complex, technologies that combine biological relevance with molecular accuracy are shifting from helpful additions to essential capabilities. Single B cell antibody discovery supports this transition by capturing naturally occurring antibodies, preserving native chain pairing, and producing sequence-defined candidates from the beginning.

  FEATURED EDITORIAL

  COMPANY PROFILE

Unsure your filling needs will be fulfilled? Have a complex injectable product or process? We say, “Bring it.” Lifecore is a U.S.-based Contract Development and Manufacturing Organization specializing in the development, fill/finish, and commercialization of sterile injectables. With a 40+ year regulatory track record and 20+ commercial products, Lifecore offers end-to-end services with experience spanning straightforward to complex formulations.  We support organizations of all sizes across pre-clinical, clinical, and commercial stages. Lifecore is also a leading producer of pharmaceutical-grade, non-animal-sourced sodium hyaluronate which is used as an API and excipient. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

       
By:
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford

The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

Abstract

Intradermal delivery has long been a critical method in medical and pharmaceutical fields, offering unique advantages for diagnosis, vaccination and therapeutic applications. This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 11 – Parenteral Contract Manufacturing
March 18 – Polymers & Biomaterials